Quantitative determination of the surfactant-induced split ratio of influenza virus by fluorescence spectroscopy

Human Vaccines and Immunotherapeutics

Volumn 12, Issue 7, 2016, Pages 1757-1765

  Lee, Kenny Kwon Ho ^a   Sahin, Yusuf Ziya ^a   Neeleman, Ronald ^b   Trout, Bernhardt L ^c   Kayser, Veysel ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b SANOFI PASTEUR   (France)

^c Massachusetts Institute of Technology   (United States)

Author keywords

fluorescence emission; fluorescence lifetime; influenza split virus vaccine; influenza virus; membrane surfactant interactions; Nile Red; partitioning of dye in membranes; protein aggregation; split ratio quantification; surfactant; Triton X 100; vaccine formulation; vaccine manufacturing; virus splitting; virus surfactant interactions

Indexed keywords

INFLUENZA VACCINE; MEMBRANE PROTEIN; SURFACTANT; INACTIVATED VACCINE; VIRUS ANTIGEN;

ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRITICAL MICELLE CONCENTRATION; DRUG MANUFACTURE; FLUORESCENCE SPECTROSCOPY; HYDROPHOBICITY; INFLUENZA VIRUS; MOLECULAR INTERACTION; NONHUMAN; PROCESS OPTIMIZATION; PROTEIN AGGREGATION; TRANSMISSION ELECTRON MICROSCOPY; CHEMISTRY; DRUG EFFECTS; METABOLISM; ORTHOMYXOVIRIDAE; SPECTROFLUOROMETRY;

ANTIGENS, VIRAL; INFLUENZA VACCINES; ORTHOMYXOVIRIDAE; SPECTROMETRY, FLUORESCENCE; SURFACE-ACTIVE AGENTS; VACCINES, INACTIVATED;

EID: 84961208203     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2016.1141846     Document Type: Article

References (23)

1. Fact sheet: Influenza (Seasonal) [Internet]. Switzerland: World Health Organization Headquarters; 2014 March [cited 2015 July]. [about 3 screens]. Available from: http://www.who.int/mediacentre/factsheets/fs211/en/
2. Overview of vaccine regulation and safety monitoring and investigation into adverse events following 2010 seasonal influenza. Alert information: Seasonal flu vaccine: Overview of vaccine regulation and safety monitoring and investigation into adverse events following 2010 seasonal influenza vaccination in young children [Internet]. Australia: Department of Health, Therapeutic Goods Administration; 2010 Oct 8 [cited 2015 July]. [about 17 screens]. Available from: https://www.tga.gov.au/alert/seasonal-flu-vaccine-overview-vaccine-regulation-and-safety-monitoring-and-investigation-adverse-events-following-2010-seasonal-influenza-vaccination-young-children
3. J.M.Belanger, Y.Raviv, M.Viard, U.Baxa, R.Blumenthal. Orthogonal inactivation of influenza and the creation of detergent resistant viral aggregates: towards a novel vaccine strategy. Virol J 2012; 9:1–12; PMID:22214262; http://dx.doi.org/10.1186/1743-422X-9-72
4. J.A.Al-Tawfiq, A.Zumla, P.Gautret, G.C.Gray, D.S.Hui, A.A.Al-Rabeeah, Z.A.Memish. Surveillance for emerging respiratory viruses. Lancet Infect Dis 2014; 14:992–1000; PMID:25189347; http://dx.doi.org/10.1016/S1473-3099(14)70840-0
5. A.Helenius, H.Soderlund. Stepwise dissociation of the Semliki Forest Virus membrane with Triton X-100. Biochemica et Biophysica Acta 1973; 307:287–300; http://dx.doi.org/10.1016/0005-2736(73)90096-5
6. D.O'Hagan Changing TH1/TH2 balance in split influenza vaccines with adjuvants In: U.Patents, ed. United States: Novartis Vaccines and Diagnostics SRL, 2009.
7. F.Geeraedts, L.Bungener, J.Pool, W.Ter Veer, J.Wilschut, A.Huckriede. Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs. Influenza Other Respir Viruses 2008; 2:41–51; PMID:19453471; http://dx.doi.org/10.1111/j.1750-2659.2008.00038.x
8. E.Patois, M.A.Capelle, R.Gurny, T.Arvinte. Stability of seasonal influenza vaccines investigated by spectroscopy and microscopy methods. Vaccine 2011; 29:7404–13; PMID:21803109; http://dx.doi.org/10.1016/j.vaccine.2011.07.067
9. T.Buranda, Y.Wu, D.Perez, A.Chigaev, L.A.Sklar. Real-time partitioning of octadecyl rhodamine b into bead-supported lipid bilayer membranes revealing quantitative differences in saturable binding sites in DOPC and 1:1:1 DOPC/SM/Cholesterol membranes. J Phys Chem B 2010; 114:1336–49; PMID:20043651; http://dx.doi.org/10.1021/jp906648q
10. P.Greenspan, E.P.Mayer, S.D.Fowler. Nile red: a selective fluorescent stain for intracellular lipid droplets. J Cell Biol 1985; 100:965–73; PMID:3972906; http://dx.doi.org/10.1083/jcb.100.3.965
11. D.L.Sackett, J.Wolff. Nile Red as a polarity-sensitive fluorescent probe of hydrophobic protein surfaces. Anal Biochem 1987; 167:228–34; PMID:3442318; http://dx.doi.org/10.1016/0003-2697(87)90157-6
12. Product Information: Triton X-100 laboratory grade [Internet]. Australia: Sigma-Aldrich; cited 2015 July. [about 6 screens]. Available from: http://www.sigmaaldrich.com/catalog/product/sial/x100?lang=en®ion=AU
13. U.Anand, C.Jash, S.Mukherjee. Spectroscopic determination of Critical Micelle Concentration in aqueous and non-aqueous media using a non-invasive method. J Colloid Interf Sci 2011; 364:400–6; PMID:21924731; http://dx.doi.org/10.1016/j.jcis.2011.08.047
14. S.Mukherjee, H.Raghuraman, A.Chattopadhyay. Membrane localization and dynamics of Nile Red: Effect of cholesterol. Biochemica et Biophysica Acta 2007; 1768:59–66; http://dx.doi.org/10.1016/j.bbamem.2006.07.010
15. D.Lichtenberg, H.Ahyayauch, F.M.Goni. The mechanism of detergent solubilization of lipid bilayers. Biophys J 2013; 105:289–99; PMID:23870250; http://dx.doi.org/10.1016/j.bpj.2013.06.007
16. P.Greenspan, S.D.Fowler. Spectrofluorometric studies of the lipid probe, nile red. J Lipid Res 1985; 26:781–9; PMID:4031658
17. J.Fontana, G.Cardone, J.B.Heymann, D.C.Winkler, A.C.Steven. Structural changes in influenza virus at low pH characterized by Cryo-Electron Tomography. J Virol 2012; 86:2919–29; PMID:22258245; http://dx.doi.org/10.1128/JVI.06698-11
18. A.Datta, D.Mandal, S.K.Pal, K.Bhattacharyya. Intramolecular charge transfer processes in confined systems. Nile red in reverse micelles†. J Phys Chem B 1997; 101:10221–5; http://dx.doi.org/10.1021/jp971576m
19. R.G.Webster, W.P.Glezen, C.Hannoun, W.G.Laver. Potentiation of the immune response to influenza virus subunit vaccines. J Immunol 1977; 119:2073–7; PMID:915292
20. V.Kayser, N.Chennamsetty, V.Voynov, B.Helk, K.Forrer, B.L.Trout. Evaluation of a non-Arrhenius model for therapeutic monoclonal antibody aggregation. J Pharmaceut Sci 2011; 100:2526–42; PMID:21268027; http://dx.doi.org/10.1002/jps.22493
21. P.Nikitas, A.Pappa-Louisi, A.Papageorgiou. On the equations describing chromatographic peaks and the problem of the deconvolution of overlapped peaks. J Chromatograp A 2001; 912:13–29; PMID:11307976; http://dx.doi.org/10.1016/S0021-9673(01)00524-6
22. V.Kayser, N.Chennamsetty, V.Voynov, B.Helk, B.L.Trout. Tryptophan-Tryptophan energy transfer and classification of tryptophan residues in proteins: Therapeutic monoclonal antibody as a model. J Fluorescence 2010; 21:275–88; PMID:20886272; http://dx.doi.org/10.1007/s10895-010-0715-0
23. P.R.Bevington. Data reduction and error analysis for the physical sciences New York: McGraw-Hill, 1969.